Accutane Risk Management Program Loosens Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
Males and females of non-child bearing potential – over half the iPLEDGE participants – can now fill their scripts even if they miss the seven-day window.
You may also be interested in...
Accutane iPLEDGE Debut On Track Despite Calls For Delay
FDA confirmed that it would not delay the March 1 implementation of the isotretinoin risk management program.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.